181 related articles for article (PubMed ID: 18579821)
1. Hypereosinophilic syndrome and mepolizumab.
Boucher RM; Gilbert-McClain L; Chowdhury B
N Engl J Med; 2008 Jun; 358(26):2838-9; author reply 2839-40. PubMed ID: 18579821
[No Abstract] [Full Text] [Related]
2. Hypereosinophilic syndrome and mepolizumab.
Verzegnassi F
N Engl J Med; 2008 Jun; 358(26):2838; author reply 2839-40. PubMed ID: 18584819
[No Abstract] [Full Text] [Related]
3. Treatment of patients with the hypereosinophilic syndrome with mepolizumab.
Rothenberg ME; Klion AD; Roufosse FE; Kahn JE; Weller PF; Simon HU; Schwartz LB; Rosenwasser LJ; Ring J; Griffin EF; Haig AE; Frewer PI; Parkin JM; Gleich GJ;
N Engl J Med; 2008 Mar; 358(12):1215-28. PubMed ID: 18344568
[TBL] [Abstract][Full Text] [Related]
4. Hypereosinophilic syndrome and mepolizumab.
Boulware DR; Stauffer WM; Walker PF
N Engl J Med; 2008 Jun; 358(26):2839; author reply 2839-40. PubMed ID: 18589879
[No Abstract] [Full Text] [Related]
5. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
Garrett JK; Jameson SC; Thomson B; Collins MH; Wagoner LE; Freese DK; Beck LA; Boyce JA; Filipovich AH; Villanueva JM; Sutton SA; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2004 Jan; 113(1):115-9. PubMed ID: 14699394
[TBL] [Abstract][Full Text] [Related]
6. Combating the eosinophil with anti-interleukin-5 therapy.
Wechsler ME
N Engl J Med; 2008 Mar; 358(12):1293-4. PubMed ID: 18344569
[No Abstract] [Full Text] [Related]
7. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome.
Sefcick A; Sowter D; DasGupta E; Russell NH; Byrne JL
Br J Haematol; 2004 Feb; 124(4):558-9. PubMed ID: 14984510
[No Abstract] [Full Text] [Related]
8. The Effect of Mepolizumab on the Lungs in a Boy with Hypereosinophilic Syndrome.
Armoni Domany K; Shiran SI; Adir D; Lavie M; Levin D; Diamant N; Gut G; Benor S
Am J Respir Crit Care Med; 2020 Jul; 202(2):e34-e35. PubMed ID: 32150442
[No Abstract] [Full Text] [Related]
9. Mepolizumab-a novel option for the treatment of hypereosinophilic syndrome in childhood.
Schwarz C; Müller T; Lau S; Parasher K; Staab D; Wahn U
Pediatr Allergy Immunol; 2018 Feb; 29(1):28-33. PubMed ID: 28986919
[TBL] [Abstract][Full Text] [Related]
10. Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib.
Koury MJ; Newman JH; Murray JJ
Am J Med; 2003 Nov; 115(7):587-9. PubMed ID: 14599646
[No Abstract] [Full Text] [Related]
11. Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5.
Mehr S; Rego S; Kakakios A; Kilham H; Kemp A
J Pediatr; 2009 Aug; 155(2):289-91. PubMed ID: 19619754
[TBL] [Abstract][Full Text] [Related]
12. Mepolizumab in eosinophilic disorders.
Abonia JP; Putnam PE
Expert Rev Clin Immunol; 2011 Jul; 7(4):411-7. PubMed ID: 21790283
[TBL] [Abstract][Full Text] [Related]
13. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
Roufosse F; de Lavareille A; Schandené L; Cogan E; Georgelas A; Wagner L; Xi L; Raffeld M; Goldman M; Gleich GJ; Klion A
J Allergy Clin Immunol; 2010 Oct; 126(4):828-835.e3. PubMed ID: 20810155
[TBL] [Abstract][Full Text] [Related]
14. [Anti-interleukin-5 therapy for eosinophilic diseases].
Simon D; Braathen LR; Simon HU
Hautarzt; 2007 Feb; 58(2):122, 124-7. PubMed ID: 17221241
[TBL] [Abstract][Full Text] [Related]
15. [Use of mepolizumab in hypereosinophilic syndromes: The position and proposals of the national reference center for hypereosinophilic syndromes].
Kahn JE; Lefèvre G; Groh M
Rev Med Interne; 2023 Apr; 44(4):155-157. PubMed ID: 36997273
[No Abstract] [Full Text] [Related]
16. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis.
Plötz SG; Simon HU; Darsow U; Simon D; Vassina E; Yousefi S; Hein R; Smith T; Behrendt H; Ring J
N Engl J Med; 2003 Dec; 349(24):2334-9. PubMed ID: 14668459
[No Abstract] [Full Text] [Related]
17. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report.
Pitini V; Teti D; Arrigo C; Righi M
Br J Haematol; 2004 Dec; 127(5):477. PubMed ID: 15566349
[No Abstract] [Full Text] [Related]
18. Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.
Kuang FL; Fay MP; Ware J; Wetzler L; Holland-Thomas N; Brown T; Ortega H; Steinfeld J; Khoury P; Klion AD
J Allergy Clin Immunol Pract; 2018; 6(5):1518-1527.e5. PubMed ID: 29751154
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.
Roufosse F; Kahn JE; Rothenberg ME; Wardlaw AJ; Klion AD; Kirby SY; Gilson MJ; Bentley JH; Bradford ES; Yancey SW; Steinfeld J; Gleich GJ;
J Allergy Clin Immunol; 2020 Dec; 146(6):1397-1405. PubMed ID: 32956756
[TBL] [Abstract][Full Text] [Related]
20. All systems red.
Karmacharya P; Donato AA; Aryal MR; Pathak R; Goonewardene M; Valent P
Am J Hematol; 2015 Apr; 90(4):356-60. PubMed ID: 25294166
[No Abstract] [Full Text] [Related]
[Next] [New Search]
